RECRUITING

The Impact of a Plant-based Meat Meal Versus an Animal Meat Meal on Erectile Function in Healthy Men.

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this study is to determine whether erectile function is differentially impacted by a single plant-based meat meal versus a single animal meat meal in healthy men with normal erectile function.

Official Title

The Impact of a Plant-based Meat Meal Versus an Animal Meat Meal on Erectile Function in Healthy Men.

Quick Facts

Study Start:2024-09-19
Study Completion:2026-09
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06273592

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 32 Years
Sexes Eligible for Study:MALE
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Subject provides written informed consent and HIPAA authorization in English before any study procedures are conducted. (If the subject is a fluent Spanish and/or other language speaker, subject must also be fluent in English (understanding and speaking) to be eligible for this study.)
  2. * IIEF score greater or equal to 22
  3. * Subject is currently taking no medication other than prn MDIs No change in supplements if applicable
  4. * Subject will have had penile sexual intercourse (either vaginal or anal penetration) within 12 weeks of enrollment
  5. * Male (biological) aged 18-32 years old
  6. * Lives within commuting distance of Montefiore Health System
  7. * Subject's significant other (if applicable) agrees to support the subject during the study
  8. * Subject agrees to avoid all illicit drugs, NSAIDS, and alcohol for at least two days prior to Rigiscan™ recording and on the days and nights of Rigiscan™ recording
  9. * Subject agrees to refrain from sexual activity for at least 24 hours prior to Rigiscan™ placement and to have no sexual activity on the days and nights of Rigiscan™ recording
  10. * Subject agrees to not view, read, or otherwise consume erotic or pornographic material for at least 24 hours prior to the days and nights of Rigiscan™ recording and on the days and nights of Rigiscan™ recording
  11. * Subject agrees to not have an orgasm for 24 hours prior to both the days and nights of Rigiscan™ recording and on the days and nights of Rigiscan™ recording
  12. * Subject agrees to come to Montefiore to undergo Rigiscan™ training
  13. * Subject agrees to only consume/drink permitted food/beverages
  14. * Subject agrees to attend all in person visits at Montefiore and to undergo all blood draws and other testing
  15. * Subject agrees to not use mouthwash or mouth rinses or intentionally spit for the entire duration of the study. Subjects will be asked to refrain from using mouthwash for at least 2 days prior to enrollment. Subject agrees to not brush his teeth and to not use toothpaste for 24 hours preceding Rigiscan testing. Tooth brushing is otherwise permissible.
  16. * BMI \<27, BMI \>=18.5, weight \>110 lbs
  17. * Subject agrees to comply with the study procedures and visits
  18. * Subject exercises for at least 15 minutes at least two times per week
  19. * If exercise is done, subjects will exercise for the same amount of time and at a similar intensity each day of Rigiscan™ testing. Otherwise, no exercise will be performed on Rigiscan™ days.
  20. * If enrolled, subjects agree to not modify their dietary habits throughout the duration of the study other than during the two evenings when food is provided.
  21. * If enrolled, subjects agree to fast when requested to fast
  1. * Relevant dietary allergy
  2. * Vegetarian or Vegan dietary pattern
  3. * History of an eating disorder and/or food addiction
  4. * Hypertension and or history of hypertension with or without medical treatment. Systolic blood pressure \> 150mmHg and/or diastolic blood pressure \>100mmHg on Visit one. Heart rate \>99 on Visit one. Systolic blood pressure \< 85mmHg and/or diastolic blood pressure \< 50mmHg on Visit one. Heart rate \< 35 on Visit one
  5. * BMI \>=27, BMI \<18.5, or weight \<= 110lbs
  6. * Known chronic medical disease other than non-inflammatory musculoskeletal disease, asthma
  7. * Subjects who are taking benzodiazepines, stimulants (e.g. for ADHD), SSRI, anti-depressants and/or beta blockers
  8. * Obstructive sleep apnea (OSA) diagnosis or an ongoing evaluation for possible OSA
  9. * Score greater than 2 on the STOP-Bang OSA screening tool
  10. * Having the diagnosis of Restless Leg Syndrome
  11. * Having insomnia as defined by: Subject with insomnia would have difficulty initiating or maintaining sleep (30 minutes or more at sleep initiation or 30 minutes or more to fall back asleep if wakes during the night). The above occurs at least 3 times per week for at least 1 month. Furthermore, there must be adequate opportunity for sleep and there must be associated morbidity (feels tired during the day). Definition based on: The International Classification of Sleep Disorders - Third Edition (ICSD-3), 2014
  12. * History of kidney disease or hyperkalemia
  13. * Subject has received an investigational drug within 30 days prior to signing consent
  14. * Erectile dysfunction
  15. * Has any condition (e.g., psychiatric illness) or situation that, in the investigator's opinion, may confound the study results, or may interfere significantly with the patient's ability to adhere with study procedures
  16. * Currently undergoing treatment for Peyronie's Disease
  17. * Abnormal Testosterone or Thyroid Stimulating Hormone level
  18. * Treated hypogonadism or hypothyroidism
  19. * Planned travel during the study
  20. * History of substance abuse in the last 12 months
  21. * Illicit drug use, smoking, or vaping within 4 weeks
  22. * Upper respiratory illness within two weeks on screening
  23. * If profession requires being on call, no overnight or on call duties during the study
  24. * Subject reports any communicable skin or venereal disease
  25. * Transgender status (Individuals who have undergone or are undergoing hormone replacement therapy or who have undergone gender affirming surgery. Individuals who plan to begin hormone replacement therapy or to undergo gender affirming surgery during the study.)
  26. * HIV positive status via direct medical history
  27. * Subject reports rash or lesion on the penis or surrounding area

Contacts and Locations

Study Contact

Robert Ostfeld, MD, MSc
CONTACT
718-920-5197
ROstfeld@Montefiore.org

Principal Investigator

Robert Ostfeld, MD, MSc
PRINCIPAL_INVESTIGATOR
Montefiore Medical Center

Study Locations (Sites)

Montefiore Medical Center
Bronx, New York, 10467
United States

Collaborators and Investigators

Sponsor: Montefiore Medical Center

  • Robert Ostfeld, MD, MSc, PRINCIPAL_INVESTIGATOR, Montefiore Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-09-19
Study Completion Date2026-09

Study Record Updates

Study Start Date2024-09-19
Study Completion Date2026-09

Terms related to this study

Keywords Provided by Researchers

  • Diet
  • Erectile function
  • Plant-based
  • Animal-based

Additional Relevant MeSH Terms

  • Erectile Dysfunction